Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women
- 128 Downloads
We performed a 1-year prospective study to see whether zoledronic acid infusion combined with percutaneous kyphoplasty could provide more benefits in the treatment of T12 or L1 osteoporotic vertebral compression fracture (OVCF).
To investigate and analyze the clinical effects of zoledronic acid (ZOL) in combination with percutaneous kyphoplasty (PKP) in the treatment of OVCF in postmenopausal women.
Included in this study were 101 postmenopausal women patients with T12 or L1 OVCF who received PKP in our hospital between August 2015 and July 2017. They were randomly assigned to a zoledronic acid (ZOL) group (n = 50) or a control group (n = 51). Patients in ZOL group were treated preoperatively with IV infusion of 5 mg ZOL in combination with 0.25μg/d calcitriol and D3 600 mg/d calcium carbonate for a year. Patients in the control group were treated with the same dose of calcitriol and calcium carbonate D3 without ZOL.
There was no statistically significant difference in age, height, weight, body mass index (BMI), menopause age, and the fractured vertebral body between the two groups. At 6 and 12 months after treatment, bone mineral density (BMD) in ZOL group was higher than that in the control group (p < 0.01); bone markers (NMID, P1NP, and β-CTX) and the VAS score in ZOL group were significantly lower than those in the control group. No new fracture occurred in ZOL group. The incidence of recompression vertebral fracture (RVF) in the control group was 11.7%, while no RVF was detected in any patient in ZOL group. Mild adverse reactions in ZOL group were significantly higher than those in the control group, but all of them were relieved after symptomatic treatment.
ZOL IV infusion in combination with PKP is beneficial for the treatment of T12 or L1 OVCF.
KeywordsOsteoporosis Osteoporotic vertebral compression fracture Percutaneous kyphoplasty Zoledronic acid
Compliance with ethical standards
Conflicts of interest
- 2.Kanis JA, Adachi JD, Cooper C, Clark P, Cummings SR, Diaz-Curiel M, Harvey N, Hiligsmann M, Papaioannou A, Pierroz DD et al (2013) Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. Osteoporos Int 24(11):2763–2764CrossRefGoogle Scholar
- 15.Bell KJ, Hayen A, Glasziou P, Irwig L, Eastell R, Harrison SL, Black DM, Bauer DC (2016) Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomized controlled trial data. J Bone Miner Res 31(9):1767–1773CrossRefGoogle Scholar
- 16.Kim BS, Yang SS, Kim CS, Lee J (2018) Zoledronate suppresses VEGFinduced capillary tube formation and inhibits expression of interferoninduced transmembrane protein1 in human umbilical vein endothelial cells. Int J Mol Med 41(5):2879–2884Google Scholar
- 17.Hagino H: [Evidence for positive effects of long-term bisphosphonate administration.]. Clin Calcium 2017, 27(2):203–211Google Scholar
- 18.Shi C, Zhang M, Cheng AY, Huang ZF: Percutaneous kyphoplasty combined with zoledronic acid infusion in the treatment of osteoporotic thoracolumbar fractures in the elderly. Clin Interv Aging 2018, 13:853–861Google Scholar
- 20.Zuo XH, Zhu XP, Bao HG, Xu CJ, Chen H, Gao XZ, Zhang QX (2018) Network meta-analysis of percutaneous vertebroplasty, percutaneous kyphoplasty, nerve block, and control treatment for nonsurgery options of acute subacute and chronic osteoporotic vertebral compression fractures (OVCFs) in short-term and long-term effects. Medicine 97(29):e11544CrossRefGoogle Scholar
- 21.Dempster DW, Roschger P, Misof BM, Zhou H, Paschalis EP, Alam J, Ruff VA, Klaushofer K, Taylor KA (2016) Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 31(8):1527–1535CrossRefGoogle Scholar
- 23.Popp AW, Senn R, Curkovic I, Senn C, Buffat H, Popp PF, Lippuner K (2017) Factors associated with acute-phase response of bisphosphonate-naive or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis\ Foundation of the USA 28(6):1995–2002CrossRefGoogle Scholar
- 24.Crotti C, Watts NB, De Santis M, Ceribelli A, Fabbriciani G, Cavaciocchi F, Marasini B, Selmi C, Massarotti M (2018) Acute phase reactions after zoledronic acid infusion: protective role of 25-hydroxyvitamin D and previous oral bisphosphonate therapy. Endocr Pract 24(5):405–410Google Scholar
- 25.Wang H, Hu ZH, Chen L, Pan Y (2016) Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis. Beijing Da Xue Xue Bao Yi Xue Ban 48(4):680–682Google Scholar
- 26.Tian Y, Wang R, Liu L, Ma C, Lu Q, Yin F (2016) Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. BMC Musculoskelet Disord 17:72CrossRefGoogle Scholar
- 27.Kulkarni P, Cushman T, Donthireddy V, Rao S (2016) Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis. BMJ Case Rep 2016Google Scholar
- 28.Kaur U, Chakrabarti SS, Gambhir IS: Zoledronate induced hypocalcemia and hypophosphatemia in osteoporosis: a cause of concern. Curr Drug Saf 2016, 11(3):267–269Google Scholar